Pharmacy professor discovers drug interaction that inhibits Tamiflu
October 25, 2006

International and federal health officials are counting on the anti-viral drug Tamiflu to be a critical weapon in the event of an influenza pandemic. But a recently completed study at the University of Rhode Island’s College of Pharmacy indicates that the drug can be rendered ineffective in patients also taking the anti-clotting drug Plavix.

Click here to read the full article

The primary focus of my research is on the understanding of how genetic and environmental factors coordinately regulate the expression of genes involved in drug response and oncogenic switch. More specifically, the research activities are designed to answer such questions as: how does genetic or environmental factor contributes to differences in drug-response? How does transcriptional regulation switch from physiological (e.g., drug-metabolism) to pathological response (oncogenesis)? And how do drugs, hormones and herbs alter respective therapeutic activity when used together? Currently, there are four ongoing projects, and these projects are closely related through sharing functionality or regulatory mechanisms.

Current Research Projects

• Genetic-based alteration on drug metabolism

• Pharmacology and toxicology of hydrolytic biotransformation

• Signaling of the pregnane X receptor

• Drug, herb, hormone, and their interaction

• DEC1 transcription factor: oncogenesis and acute-phase response

Office Phone: (401) 874-5032
Lab Phone: (401) 874-5028
Fax: (401) 874-5787/2516
E mail: byan@uri.edu

University of Rhode Island
237 Fogarty Hall, 41 Lower College Road
Kingston, RI 02881

© University
of Rhode Island
Disclaimer

The University is an affirmative action/equal opportunity employer.
All rights reserved